Renaissance Technologies
TRVI icon

Renaissance Technologies’s Trevi Therapeutics TRVI Stock Holding History

Renaissance Technologies’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-293,300
Closed -$2.68M – 3768
2025
Q3 		$2.68M Sell
293,300
-196,000
-40% -$1.47M ﹤0.01% 1883
2025
Q2 		$2.68M Buy
489,300
+400,400
+450% +$2.49M ﹤0.01% 1926
2025
Q1 		$559K Sell
88,900
-11,500
-11% -$54.9K ﹤0.01% 2697
2024
Q4 		$414K Buy
100,400
+29,700
+42% +$95.1K ﹤0.01% 2930
2024
Q3 		$236K Buy
70,700
+18,800
+36% +$55.9K ﹤0.01% 3070
2024
Q2 		$155K Sell
51,900
-64,942
-56% -$180K ﹤0.01% 3100
2024
Q1 		$403K Sell
116,842
-425,858
-78% -$950K ﹤0.01% 2959
2023
Q4 		$727K Buy
542,700
+475,400
+706% +$720K ﹤0.01% 2585
2023
Q3 		$147K Sell
67,300
-22,000
-25% -$49.7K ﹤0.01% 3161
2023
Q2 		$213K Sell
89,300
-148,100
-62% -$373K ﹤0.01% 3280
2023
Q1 		$439K Sell
237,400
-80,600
-25% -$182K ﹤0.01% 2950
2022
Q4 		$614K Sell
318,000
-101,187
-24% -$199K ﹤0.01% 2833
2022
Q3 		$646K Buy
419,187
+267,687
+177% +$878K ﹤0.01% 2766
2022
Q2 		$426K Buy
151,500
+35,500
+31% +$87.2K ﹤0.01% 3249
2022
Q1 		$255K Sell
116,000
-221,400
-66% -$229K ﹤0.01% 3543
2021
Q4 		$264K Buy
337,400
+271,900
+415% +$285K ﹤0.01% 3400
2021
Q3 		$92K Sell
65,500
-27,100
-29% -$48K ﹤0.01% 3330
2021
Q2 		$208K Sell
92,600
-29,249
-24% -$65.9K ﹤0.01% 3236
2021
Q1 		$330K Buy
121,849
+96,149
+374% +$282K ﹤0.01% 3030
2020
Q4 		$62K Buy
+25,700
New +$83.2K ﹤0.01% 3308

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Renaissance Technologies's TRVI Position: Q4 2025 in Review

Renaissance Technologies sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 293,300 shares — an estimated $2.68M sold.

Renaissance Technologies first reported a position in TRVI in Q4 2020 and held it in 20 quarters. The position peaked at $2.68M in Q3 2025. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • Renaissance Technologies reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 293,300 Trevi Therapeutics shares in Q4 2025, an estimated $2.68M.
  • Renaissance Technologies first reported a position in Trevi Therapeutics in Q4 2020 and held it in 20 quarters.
  • Renaissance Technologies's Trevi Therapeutics position peaked at $2.68M in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.